alarming patients about the safety of Humira (adalimumab) and Remicade (infliximab)

July 2006

A recent analysis is alarming patients about the safety of Humira (adalimumab) and Remicade (infliximab).

These TNF inhibitors are wonder drugs for many patients with rheumatoid arthritis, Crohn's, and other autoimmune diseases.

But there's concern about an increased risk of serious infections and malignancies.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote